Most Read Articles
Jairia Dela Cruz, 10 Sep 2019
Use of aspirin in the primary prevention of cardiovascular disease (CVD) in patients with no prior CVD history yields protection against the risks of acute myocardial infarction (AMI) and ischaemic stroke, but at the expense of an increase of similar magnitude in the incidence of major bleeding, according to the results of a recent meta-analysis presented at the European Society of Cardiology (ESC) Congress 2019 in Paris, France.
Dr Margaret Shi, 6 days ago

A comprehensive model of care delivered by nonphysician health workers (NPHWs), involving primary care physicians and families that was informed by local context, substantially improved blood pressure (BP) control and cardiovascular disease (CVD) risk, according to results of the HOPE 4 trial reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.

Psoriasis drug may help fight coronary plaques

10 Feb 2019

Biologic therapies for severe psoriasis appear to help reduce noncalcified coronary plaques and improve plaque morphology, a recent study has shown.

Researchers conducted a prospective observational study including 121 psoriasis patients, of whom 89 received biologic treatments (mean age 49.1±12.2 years; 56 percent male) and 32 (mean age 51.2±12.0 years; 63 percent male) were treated with other agents. Participants tended to have low cardiovascular risk (median Framingham score, 3) with moderate-to-severe skin disease (median Psoriasis Area and Severity Index [PASI], 8.6).

After a year of follow-up, patients who were treated with biologic agents showed significant improvements in the PASI score (64-percent improvement, p<0.001), as well as a significant reduction in high-sensitivity C-reactive protein levels (p<0.001). No such changes were observed in the comparison group.

Moreover, a 5-percent decrease in total coronary plaque burden was observed in participants on biologic therapy (p=0.009), an effect primarily driven by a drop in the noncalcified plaque burden (p=0.005). No improvements in fibrous burden (p=0.71) were reported, though fibro-fatty (p=0.004) and necrotic (p=0.03) burdens decreased.

In comparison, those receiving nonbiologic interventions showed no significant 1-year change in total plaque burden (p=0.22), noncalcified plaque burden (p=0.17) and fibrous burden (p=0.22). There was also an increase in fibro-fatty burden (p=0.004).

Intergroup comparisons showed that the 1-year reduction in noncalcified plaque was significantly greater in patients treated with biologic agents (p=0.03) even after adjustments for cardiovascular risk factors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 10 Sep 2019
Use of aspirin in the primary prevention of cardiovascular disease (CVD) in patients with no prior CVD history yields protection against the risks of acute myocardial infarction (AMI) and ischaemic stroke, but at the expense of an increase of similar magnitude in the incidence of major bleeding, according to the results of a recent meta-analysis presented at the European Society of Cardiology (ESC) Congress 2019 in Paris, France.
Dr Margaret Shi, 6 days ago

A comprehensive model of care delivered by nonphysician health workers (NPHWs), involving primary care physicians and families that was informed by local context, substantially improved blood pressure (BP) control and cardiovascular disease (CVD) risk, according to results of the HOPE 4 trial reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.